Vir Biotechnology (VIR) Non-Current Assets (2018 - 2026)
Vir Biotechnology recorded quarterly Non-Current Assets of $502.6 million in Q1 2026, up 2.84% quarter-over-quarter from $488.7 million in Q4 2025, and up 33.84% year-over-year from $375.5 million in Q1 2025.
Vir Biotechnology's Non-Current Assets history runs 9 years deep, the most recent figure standing at $502.6 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 33.84% year-over-year to $502.6 million; the TTM figure through Mar 2026 stood at $1.9 billion (up 16.7% YoY), while the FY2025 annual figure was $488.7 million, up 37.15% from the prior year.
- Non-Current Assets came in at $502.6 million for Q1 2026 at Vir Biotechnology, up from $488.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $580.9 million in Q1 2024 to a low of $275.7 million in Q3 2023.
- A 5-year average of $386.9 million and a median of $356.4 million in 2024 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets jumped 124.31% in 2022 and plunged 35.35% in 2025, its largest moves.
- Vir Biotechnology's Non-Current Assets stood at $283.0 million in 2022, then rose by 16.9% to $330.8 million in 2023, then grew by 7.71% to $356.4 million in 2024, then jumped by 37.15% to $488.7 million in 2025, then rose by 2.84% to $502.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $502.6 million, $488.7 million, and $473.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | 502.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 502.60 Mn |
| Dec 31, 2025 | 488.74 Mn |
| Sep 30, 2025 | 473.77 Mn |
| Jun 30, 2025 | 456.83 Mn |
| Mar 31, 2025 | 375.52 Mn |
| Dec 31, 2024 | 356.36 Mn |
| Sep 30, 2024 | 451.20 Mn |
| Jun 30, 2024 | 463.82 Mn |
| Mar 31, 2024 | 580.87 Mn |
| Dec 31, 2023 | 330.83 Mn |
| Sep 30, 2023 | 275.72 Mn |
| Jun 30, 2023 | 297.54 Mn |
| Mar 31, 2023 | 307.30 Mn |
| Dec 31, 2022 | 283.01 Mn |
| Sep 30, 2022 | 282.35 Mn |
| Jun 30, 2022 | 330.73 Mn |
| Mar 31, 2022 | 319.58 Mn |
| Dec 31, 2021 | 391.45 Mn |
| Sep 30, 2021 | 143.88 Mn |
| Jun 30, 2021 | 195.29 Mn |
| Mar 31, 2021 | 142.47 Mn |
| Dec 31, 2020 | 146.40 Mn |
| Sep 30, 2020 | 93.69 Mn |
| Jun 30, 2020 | 93.48 Mn |
| Mar 31, 2020 | 99.57 Mn |
| Dec 31, 2019 | 109.08 Mn |
| Sep 30, 2019 | 84.92 Mn |
| Dec 31, 2018 | 73.81 Mn |